Purpose The phosphatidylinositol 3-kinase (PI3K)/ PTEN/AKT/mTOR and Ras/Raf/MEK/ERK pathways have been implicated in endometrial tumorigenesis. In this candidate pathway analysis, we investigated associations between genetic variations in these two pathways and both risk and clinical outcomes of endometrial cancer. Methods We genotyped a total of 48 potentially functional SNPs in 11 key genes (AKT1, AKT2, AKT3, BRAF, FRAP1, KRAS, PDPK1, PIK3CA, PIK3CB, PIK3R1, and PTEN) with the Sequenom genotyping platform in 115 endometrial cancer patients and 230 cancer-free women to evaluate their associations with risk, survival, and recurrence of endometrial cancer. Results We found the following: (1) PIK3CA rs6443624 and rs9838411 variants either borderline or signiWcantly decreased risk of endometrial cancer in a dominant model (adjusted odds ratio [OR], 0.62; 95% CI, 0.39-1.00 and 0.59; 95% CI, 0.36-0.95, respectively). Furthermore, there was a statistically signiWcant multiplicative interaction (P int = 0.036) between these two loci in risk of endometrial cancer. In contrast, the AKT1 rs2498801 genotype signiWcantly increased risk of endometrial cancer (adjusted OR, 1.94; 95% CI, 1.02-3.67 in a recessive model). (2) In Cox regression analyses, three SNPs (PIK3R1 rs1862162, AKT2 rs892119, and PIK3CA rs2699887) showed signiWcant associations with survival of endometrial cancer patients. (3) KRAS rs7312175 and PIK3CA rs6443624 had signiWcant eVects on recurrence of endometrial cancer individually and combined in a locus-dosage manner (adjusted P trend = 0.003). Conclusion These results suggest that common genetic variations in these pathways may modulate risk and clinical outcomes of endometrial cancer. Further replication and functional studies are needed to conWrm these Wndings.
Introduction
Endometrial cancer is the most common invasive gynecologic malignancy and the fourth most common cancer among women in developed countries. In the United States, it is estimated that there will be 46,470 new diagnoses of endometrial cancer and 8,120 disease-related deaths in 2011 (Siegel et al. 2011 ). The accumulated evidence indicates that exposure to high-level estrogen is an important risk factor for endometrial cancer (Akhmedkhanov et al. 2001) . However, individuals with a family history of endometrial cancer have a 1.3-1.8-fold increased risk of endometrial cancer, suggesting genetic susceptibility to the development of endometrial cancer (Paynter et al. 2005) .
In the past few decades, important biological pathways have been investigated for their involvement in the development of endometrial carcinoma, including the phosphatidylinositol 3-kinase (PI3K)/PTEN/AKT/mTOR and RAS/ RAF/MEK signaling pathways (Ninomiya et al. 2004; Steelman et al. 2008 ). These two pathways are activated by many growth factors and cytokines and subsequently play critical roles in driving cell proliferation and preventing apoptosis (Nicholson and Anderson 2002; McCubrey et al. 2006) . The estrogen receptor further interacts with the PI3K/PTEN/AKT/mTOR pathway at multiple levels, supporting potential crosstalk between estrogens and the PI3K pathway (Kirkegaard et al. 2005; Antico-Arciuch et al. 2010) . Abnormal regulation of the PI3K and RAS pathways induced by mutations in Ras and B-Raf as well as other genes (e.g., PI3K, PTEN, and AKT) occurs in a wide range of tumor types, and there is extensive evidence validating various components of these pathways as molecular targets for cancer therapy (Li et al. 1997; Lynch et al. 2004; Samuels et al. 2004; Carpten et al. 2007; Steelman et al. 2010) . For endometrial cancer, inactivating mutations in PTEN and activating mutations in KRAS and PIK3CA have been reported to occur in 30-50, 10-30, and 30-40% of endometrial cancers, respectively (Yuan and Cantley 2008) . Furthermore, mutations or overexpressions of genes involved in these pathways have been associated with invasion, metastasis, and prognosis of a variety of cancers, including endometrial cancer (Minaguchi et al. 2001; Catasus et al. 2008; Chen et al. 2009; Rudd et al. 2011; Urick et al. 2011) . The role of somatic mutations in these pathways in determining patient outcomes is both complex and dependent on interactions with other events (Mori et al. 2007; Catasus et al. 2008 Catasus et al. , 2009 Konstantinova et al. 2010; Murayama-Hosokawa et al. 2010; Urick et al. 2011) but suggests that evaluation of the role of germline mutations in initiation and progression of endometrial cancer is clearly warranted.
Common genetic variations, such as single-nucleotide polymorphisms (SNPs), may modulate the function of genes in PI3K and RAS/RAF signaling pathways, resulting in both predisposition to and altered clinical outcomes of endometrial cancer. Some SNPs in genes involved in these two pathways have been implicated in risk of ovarian and colorectal cancer (Li et al. 2008; Quaye et al. 2009) , and other SNPs with prognosis of esophageal and lung cancer Pu et al. 2010) . However, few studies have investigated the association between SNPs of genes in these pathways and endometrial cancer development (Treloar et al. 2007; Wang et al. 2009 ). Therefore, we conducted this pilot case-control study to examine the associations between 48 potentially functional SNPs in 11 core genes (AKT1, AKT2, AKT3, BRAF, FRAP1, KRAS, PDPK1, PIK3CA, PIK3CB, PIK3R1, and PTEN) in these two pathways and risk and clinical outcomes of endometrial cancer.
Materials and methods

Study subjects
MD Anderson Cancer Center is a tertiary referral center, and the patient population may be skewed toward cases of advanced or recurrent cancers and therefore not representative of cases from the general population. The 115 incident patients with newly diagnosed and histologically conWrmed endometrial cancer included in this study therefore represented only approximately 3% of all uterine cancer patients seen at MD Anderson during the period of 2000-2008 with both blood samples collected and clinical follow-up data available for analysis. Peripheral blood samples were collected during surgery by the Gynecologic Cancer Tumor Bank at The University of Texas M.D. Anderson Cancer Center. The 230 healthy cancer-free women were randomly selected as controls from a large repository of controls enrolled in an ongoing lung cancer case-control study, recruited from a multispecialty physician group in Houston. Controls were selected from the same time period as the cases, frequency-matched to the patients on age, ethnicity, and smoking status (never, former, or current). One milliliter of whole blood was used for genomic DNA extraction with a DNA blood Mini Kit (Qiagen Inc., Valencia, CA) according to the manufacturer's instructions. Demographic data and environmental exposure history were obtained from structured questionnaires administered to the controls and from a core self-administered questionnaire and chart review for the cases. Tumors were staged according to the TNM classiWcation and grouped as early clinical stage (I-II) or advanced clinical stage (III-IV). All cases were followed up after surgical treatment until death, disease recurrence, or date of last follow-up. The average follow-up time was 29.24 months, and the last follow-up date was October 8, 2009.
SNP selection and genotyping
Polymorphisms were selected by an approach combining both tagging SNPs and potentially functional SNPs for 11 genes (AKT1, AKT2, AKT3, BRAF, FRAP1, KRAS, PDPK1, PIK3CA, PIK3CB, PIK3R1, and PTEN) . SNPs selected met one of the following criteria: (1) Table 1 ). The information about assay conditions, primers, and probes is available upon request. All samples were run in duplicates with call rates of >95%, and all output spectra were visually inspected.
Statistical analysis
The chi-square ( 2 ) test was used to determine whether genotype distributions were in Hardy-Weinberg equilibrium (HWE) in the controls. The associations between genotypes and endometrial cancer risk were estimated by computing odds ratios (ORs) and 95% conWdence intervals (CIs) from both univariate and multivariate logistic regression analyses with adjustment for age, ethnicity, and smoking. The Kaplan-Meier method and the log-rank test were used to analyze associations between survival and demographic characteristics, clinical features, and SNPs. Univariate or multivariate Cox regression analyses were performed to determine predictive factors of endometrial cancer prognosis by estimating crude and adjusted hazard ratios (HRs) and their 95% conWdence intervals (CIs). All statistical analyses were two-sided, and P < 0.05 was considered statistically signiWcant. Statistical Analysis System software (version 9.2; SAS Institute, Cary, NC) and PLINK whole-genome association analysis toolset were used for the statistical analyses.
Results
Patient characteristics
The demographic features of the 115 endometrial cancer patients and 230 cancer-free women controls are summarized in Table 1 . The majority (76.2%) of the participants were non-Hispanic whites, the others included 10 (8.7%) African-Americans and 17 (14.8%) Mexican-Americans. The distributions of age and ethnicity between the cases and controls were almost identical (P = 0.94 and 0.93, respectively). About 48.2% (54/112) and 32.4% (36/111) of the cases received radiotherapy and chemotherapy after surgery, respectively. Of the total 115 endometrial cancer cases, 60.9% had early stages of I-II, 39.1% had advanced stages (III-IV), 67 (58.3%) were pure endometrioid, 37 (32.1%) were mixed (endometrioid with clear cell or papillary or serous, etc.), and 11 (9.6%) were other types including MMMT (malignant mixed Müllerian tumor) and other sarcomas.
Association between SNPs and susceptibility to endometrial cancer
Analysis for single locus
Among the 48 SNPs listed in Supplemental Table 1 , three SNPs (rs7636454 in PIK3CA, rs61764374 in KRAS, and rs10866 in PDPK1) had a MAF <0.05 in controls, seven SNPs were not in HWE (P < 0.05; rs8100018 in AKT2, rs1770345 in FRAP1, rs7960917, rs8720 and rs7312175 in KRAS, and rs12573787 and rs12357281 in PTEN), and two SNPs (rs12124983 in FRAP1 and rs4854955 in PIK3CA) had a high LD (linkage disequilibrium) with rs2295080 in FRAP1 and rs2865084 in PIK3CA, respectively. As a result, 12 SNPs were excluded from the Wnal analysis for susceptibility to endometrial cancer. We used three genetic models (additive, dominant and recessive) to investigate the associations between genotypes of the remaining 36 SNPs and endometrial cancer risk (Supplemental Table 1 ). Three SNPs (AKT1 rs2498801, PIK3CA rs6443624, and PIK3CA rs9838411) had a P value <0.05 in at least one model and were selected for further analysis. After adjustment for age, ethnicity, and smoking status, logistic regression analysis (Table 2) demonstrated that both PIK3CA rs6443624 and rs9838411 remained borderline or signiWcantly associated with decreased risk of endometrial cancer in a dominant model (adjusted OR, 0.62; 95% CI, 0.39-1.00 for rs6443624 and adjusted OR, 0.59; 95% CI, 0.36-0.95 for rs9838411); in contrast, AKT1 rs2498801 was signiWcantly associated with increased risk of endometrial cancer (adjusted OR, 1.94; 95% CI, 1.02-3.67 in a recessive model) ( Table 2) . No signiWcant associations were found between the other 33 SNPs and endometrial cancer risk (detailed data not shown).
Analysis for combined eVects and interactions of SNPs
To evaluate any combined eVects of these three variants, we summed the number of protective alleles (i.e., rs2498801 A, rs6443624 A, and rs9838411 A) and observed a signiWcant locus-dosage eVect between favorable alleles and endometrial cancer risk (adjusted P trend = 0.009). As shown in Table 2 , those subjects with 2 and >2 protective alleles had 23 and 52% reduced risk (OR, 0.77; 95% CI, 0.43-1.35 and OR, 0.48; 95% CI, 0.27-0.83, respectively) of endometrial cancer, compared to those with 0-1 protective alleles. Furthermore, a statistically signiWcant multiplicative interaction (P int = 0.036) between two loci of PIK3CA (rs6443624 and rs9838411) was found in risk of endometrial cancer.
Association between SNPs and clinical outcomes of endometrial cancer
Analysis for associations between clinical features and overall survival
Complete follow-up data were available for 115 patients with 20 deaths. The follow-up time ranged from 0.2 to 118 months with the mean of 29.4 months. Clinical stage, radiotherapy, and histology were signiWcantly associated with survival time (log-rank P = 0.004, 0.025, and <0.001, respectively); ethnicity and chemotherapy had no association with survival (log-rank P = 0.156 and 0.059, respectively); age was borderline signiWcant (P = 0.051). 
Analysis for eVects of genetic variants on survival of endometrial cancer patients
Of the 45 common SNPs, Cox regression analyses showed that three SNPs (rs1862162 in PIK3R1, rs892119 in AKT2, and rs2699887 in PIK3CA) exhibited signiWcant associations with the hazard of death. As shown in Table 3 , after adjustment for age, ethnicity, smoking status, stage, radiotherapy, chemotherapy, and histology, rs1862162 and rs892119 variant genotypes remained signiWcantly associated with increased hazard ratios (adjusted HR, 2.75; 95% CI, 1.03-7.37 for rs1862162 in a dominant model; and adjusted HR, 11.58; 95% CI, 1.07-125.04 for rs892119 in a recessive model); in contrast, rs2699887 variant genotypes was signiWcantly associated with a lower hazard (AG vs. GG: adjusted HR, 0.24; 95% CI, 0.07-0.87). No statistically signiWcant associations were found between other SNPs and survival (detailed data not shown).
To identify independent prognostic factors for endometrial cancer, we next performed a multivariate stepwise Cox regression analysis including demographic characteristics (ethnicity and age), clinical features (stage, histology, radiotherapy, and chemotherapy), and genotypes of abovementioned three signiWcant SNPs on survival of endometrial cancer patients. At last, Wve variables (histology, radiotherapy, age, PIK3R1 rs1862162 heterozygosity, and PIK3CA rs2699887 heterozygosity) remained as signiWcant prognosticators in the regression model with a signiWcance level of P < 0.05 (Table 4) .
Analysis for eVects of genetic variants on endometrial cancer recurrence
There were data on recurrence for 104 patients, and 28 of them had such a recurrence. On Cox regression analyses, variant genotypes of these two SNPs exhibited increased risk of recurrence (adjusted HR, 3.82; 95% CI, 1.58-9.23 for rs7312175 in a dominant model; and adjusted HR, 5.22; 95% CI, 1.43-19.03 for rs6443624 in a recessive model). Furthermore, when we combined these two variants, we found a signiWcant locus-dosage eVect on recurrence risk (adjusted P trend = 0.003). As shown in Table 5 , compared to patients with "0" risk alleles, patients with "1" or "2-4" risk alleles of these 2 SNPs had a 2.92-and 7.36-fold increased recurrence risk (95% CI, 0.99-9.61 and 1.99-27.15, respectively) after adjustment for age, ethnicity, smoking status, histology, stage, and treatment status. Figure 1 showed the Kaplan-Meier curves of recurrencefree survival in 104 endometrial cancer patients by KRAS rs7312175 genotypes (GA/AA vs. GG: log-rank P = 0.001) and by PIK3CA rs6443624 genotypes (AA vs. CC/CA: logrank P = 0.005). 
Discussion
The PI3K/PTEN/AKT/mTOR and Ras/Raf/MEK/ERK signaling pathways play an important role in cell cycle progression, gene expression, apoptosis, drug resistance, and sensitivity to targeted therapy (McCubrey et al. 2006; Abrams et al. 2010; Steelman et al. 2010) . In these pathways, PI3K is Wrst activated by growth factors and cytokine receptor ligation and subsequently induces a kinase cascade through AKT and mTOR (Manning and Cantley 2007) . PI3Ks are members of an intracellular lipid kinase family, composed of catalytic and regulatory subunits encoded by separate genes and alternative splicing (Philp et al. 2001) . Among those, PIK3CA encodes the p110 catalytic subunit of class IA PI3Ks, and the genetic alterations in the PIK3CA gene have been reported in a wide variety of human malignancies, including endometrial cancer (Hayes et al. 2006; Catasus et al. 2008) . Recently, epidemiological studies showed that a SNP in PIK3CA (rs2865084) was associated with risk of endometrioid ovarian cancer (P trend = 0.0344) (Quaye et al. 2009 ), PIK3CA rs2677764 tagSNP was statistically signiWcantly associated with endometrial cancer (Lacey et al. 2011 ) and another SNP in PIK3CA (rs2699887) was associated with toxicity for lung cancer patients receiving platinum-based chemotherapy (Pu et al. 2010) .
In our study, we found that three SNPs (rs6443624, rs9838411, and rs2699887) located in the intron of PIK3CA were signiWcantly associated with susceptibility, survival, or recurrence of endometrial cancer, supporting the importance (1) these potentially functional tagging SNPs are the proxies of other functional SNPs within that region in the genome; and (2) bioinformatics tools have showed that rs9838411 and rs2699887 may aVect the binding of transcription factors (http://pupasuite2.bioinfo.cipf.es/ and (http://manticore.niehs.nih.gov/snpfunc.htm). Therefore, these potentially functional variants may alter normal splicing patterns or transcription of the PIK3CA gene. Intriguingly, our results showed that rs6443624 had an inconsistent eVect on the disease risk and recurrence of endometrial cancer, possibly due to diVerent biological roles of this gene in the initiation and progression of endometrial cancer. Furthermore, the presence of a locus-locus interaction between rs6443624 and rs9838411 in PIK3CA suggested the complexity of eVects of genetic variants on the development of endometrial cancer and warrants additional mechanistic investigations. PIK3R1 is another member of the PI3Ks family and encodes the p85 regulatory subunit (Arcaro and Guerreiro 2007) . Functional studies showed that a SNP in codon326 of PIK3R1 (rs3730089, Met > Ile) results in reduced p85 protein expression and increased binding to IRS-1, which negatively regulates the PI3K signaling and super-activates this pathway (Almind et al. 2002; Luo and Cantley 2005) . Moreover, a case-control study including 421 colon cancer cases and 483 controls reported that this SNP signiWcantly increased the risk of colon cancer in American population (Li et al. 2008) . Nevertheless, our results did not Wnd an association between rs3730089 and risk of endometrial cancer. However, we found the heterozygosity of another SNP of PIK3R1, rs1862162, was an unfavorable prognostic factor for endometrial cancer. The SNP rs1862162 is located in the 5Ј region near the PIK3R1 gene, and this variant may play a role in survival by aVecting the transcription and expression of PIK3R1. In addition, we also found that rs2498801 in the 3Ј UTR of AKT1 was associated with an increased risk of endometrial cancer. AKT1 is one of three isoforms of AKTs (AKT1, AKT2, and AKT3), which are major downstream targets of growth factor receptor tyrosine kinases that signal through PI3K (Testa and Bellacosa 2001) . Mounting evidence indicates that alterations in AKT proteins play an important role in regulating cell survival and growth, thus contributing to the pathogenesis of cancer (Bellacosa et al. 2005) .
KRAS is a small G protein member of RAS family (N-, H-, and KRAS). Mutations of the KRAS gene have been implicated in the development and/or progression of numerous endometrial malignancies (Mizuuchi et al. 1992; Oehler et al. 2003; Abal et al. 2006; Lax 2007 ). However, we only found that rs7312175 in KRAS was associated with the recurrence of endometrial cancer. Bioinformatics tools show that rs7312175 in KRAS is located in the transcription factor binding site. Therefore, this SNP may result in the variation of transcription activity and expression of KRAS, which can aVect the recurrence of endometrial cancer.
In this pilot study, we investigated potentially functional SNPs in 11 key genes involved in the PI3K/PTEN/AKT/ mTOR and RAS/RAF/MEK/ERK pathways and provided the evidence that variations in these pathways play a role in modulating susceptibility, survival, or recurrence of endometrial cancer. However, several limitations exist in our present study. Firstly, the small sample size limits the statistical power of our study, especially for subgroups. Therefore, we did not present the preliminary Wndings from the stratiWcation analysis. For example, we found that there were signiWcant diVerences in PIK3R1 rs3756668 and PTEN rs701848 genotype frequencies between endometrioid and non-endometrioid carcinomas (P = 0.007 and 0.003, respectively). Both SNPs were located in 3Ј-UTR of the genes, which may have eVects on the gene and protein expression. This might be a clue for diVerent carcinogenic pathways in histology types. However, the functions of these regulatory SNPs need to be investigated in cell lines or xenografts in additional mechanistic studies. We have also performed the analysis on all subjects and in Whites only separately. The trends in the analysis of both risk assessment and clinical outcomes were similar. Therefore, we did not exclude the 23% minorities from the analysis to avoid diminishing of the power. Secondly, we do not have the complete information such as age at menarche/menopause, overweight/obese status, use of estrogen therapy, nulliparity, family history, and the presence of HNPCC (hereditary non-polyposis colorectal cancer), diabetes and PCOS (polycystic ovary syndrome) for most of controls and some of the cases. Therefore, we only included the available data on demographic and exposure in the analysis. Thirdly, multiple SNPs were included in the analyses, which might result in false-positive Wndings due to multiple comparisons. The signiWcant SNPs PIK3CA rs6443624 and rs9838411 (in LD with rs7641983, r 2 = 0.966) associated with susceptibility to endometrial cancer in the present analysis were not validated in a population-based case-control study in Poland (PECS) (Lacey et al. 2011) . Finally, the functional signiWcance of these identiWed SNPs was not clear. For example, how do the three SNPs rs6443624, rs9838411, and rs2699887 play diVerent roles in susceptibility, survival, or recurrence of endometrial cancer in the same PIK3CA gene? In our correlation analysis of SNPs and available corresponding gene expression data from 9 tumor tissues, we found that PIK3CA rs2699887 (in LD with rs2699905, r 2 = 1.0) was signiWcantly associated with the PIK3CA gene expression levels measured with three probes in AVymatrix gene expression platform (data not shown). Therefore, additional profound studies with large sample sizes, genome-wide association, and mechanistic studies are warranted to unravel the biological relevance of these SNPs and the underlying molecular mechanisms for the observed associations.
